Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
about
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentComprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic.Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.Anticancer drug targets: growth factors and growth factor signaling.Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesPhage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibromaA novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.Anti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumabNanocell targeting using engineered bispecific antibodies.Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancerAssociation of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft modelsAnti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-lifeA phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.Cancer therapeutic antibodies come of age: targeting minimal residual disease.EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012.Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancerDosimetry and first human experience with 89Zr-panitumumabTumor-associated antigens for specific immunotherapy of prostate cancerIntegrating anti-EGFR therapies in metastatic colorectal cancer.
P2860
Q24652337-C3A23E81-0646-41C0-977A-CD6305F5BA06Q26751473-1312655A-BB7C-4DEC-90E7-D38179EFA624Q26771952-092DFE6C-DDDE-4A1D-9601-710503346764Q28533949-2C044D8C-31D6-4751-8EF3-91F1C3E9ADABQ33334044-CBE1967C-ECF9-4BF9-8504-C68823B614BDQ33576327-FBD43BA6-03CB-4342-AF31-7A0F584C452EQ33808352-FD7546A9-260A-4AD5-BD29-029EA00447C2Q33916016-72ABAFA1-12D6-4FED-AE6C-73931C063FDAQ33983663-10DCF338-10B6-4A63-8B58-19473E19B0AFQ34088424-C2709A2E-EF6A-4415-B3A8-2DFE2B67B338Q34385892-363004D7-E48A-45D0-92C3-C1E543EBCF8EQ34404779-1C38E0AC-2422-4521-BB35-2D0148AEAE03Q35088274-EAC3626E-FE9F-47F7-B8AB-03B2C51F6E4FQ35199371-CFB79124-3ECA-4586-9369-0ECDFA47F98BQ35569418-4B2B2596-19BD-4CFA-846B-445991E74060Q35600809-30EA21BB-6DC7-4A56-A84F-8FDD65AF929DQ35747496-72D63325-3F0D-4FF9-B2E6-18CA5434857FQ35750258-30FDF0C0-E7DD-4888-81EB-134352168C26Q35803276-A592685B-6F88-41FE-A23C-54F84DBC2AB3Q35877954-A3CD8A0A-DE70-4BB5-92CD-650590E10717Q36141923-44D085C3-DD32-47D4-A8F9-0238BA4350BCQ36211456-26430D9D-B446-437B-B363-52E28A75C628Q36213066-93BBC228-ECB0-4DA6-8261-B115DC628EA6Q36402296-F3695597-8FD8-4529-8104-CBC5810E4B57Q36610680-94AC8B7D-CA1F-4DBF-B3E3-C7B7AD340E3AQ36623819-1D445189-C183-4B29-945A-9E5303B62684Q36629392-4F3AC1CC-B3AD-416B-B251-1791B3A8A4DCQ36953914-16D5624D-2969-440F-8658-DAA20FBE25DAQ36973778-473714BC-B072-4CF2-8813-8524A6BBC08FQ37395272-099D32C3-3794-4C86-ABD3-6D761B519F3DQ37453793-BECAE76B-4E0E-4A51-B88C-A1410F78B481Q37552436-6E9D1197-1D4F-4001-ADD2-83EA2525CD84Q38096367-C698AE66-B3A5-4778-A912-30E0285AB32EQ38172182-B4401875-25E4-4D69-886A-CEF4F1A2E7EAQ38175030-8A2AF720-007D-484D-BDE3-7F77DD8D944EQ39167876-B2944B53-551A-4A48-973F-0ED9FE223CE2Q39939644-0F3C76D6-5057-42ED-92A6-744C60150E3FQ41180495-FE25D14A-DE36-42BC-B9B9-21B4BFB0E11CQ41977894-AFAD442D-96FC-424A-836F-9DD40E4610CFQ43090496-DEFB86AC-4C23-4AE6-BE54-713E779BA0B0
P2860
Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Eradication of established tum ...... hout concomitant chemotherapy.
@en
type
label
Eradication of established tum ...... hout concomitant chemotherapy.
@en
prefLabel
Eradication of established tum ...... hout concomitant chemotherapy.
@en
P2093
P1433
P1476
Eradication of established tum ...... hout concomitant chemotherapy.
@en
P2093
P304
P407
P577
1999-03-01T00:00:00Z